Modulate Bio is making medicines to help millions of patients struggling with debilitating neurological disorders. Our fine-tuned therapies bind to specific brain receptors and restore healthy function, without over-activation. By avoiding this over-activation, we provide safe, effective treatments patients can take long-term. Our team is now identifying a lead drug to bring to human clinical trials in Essential Tremor, followed closely by epilepsy and anxiety. We are excited to advance the first novel treatment to help Essential Tremor patients, families, and caretakers in over half a century.
Modulate Bio
Pagliuca Harvard Life Lab
Modulate Bio
Developing therapies to treat neurological disorders, including Essential Tremor, epilepsy, and anxiety.
Founders
Andrew Thomson
Harvard Business School
Kevin Hodgetts
Harvard Medical School
Dario Doller
Non-Harvard Affiliate
Mitchell Buckley
Non-Harvard Affiliate
About Modulate Bio
Term
2024 Fall
School
Harvard Business School
Programs
Pagliuca Harvard Life Lab, Membership
